BOOK
Management of Medication-related Osteonecrosis of the Jaw, An Issue of Oral and Maxillofacial Clinics of North America 27-4, E-Book
(2016)
Additional Information
Book Details
Abstract
Editor Salvatore Ruggiero, DMD, MD and authors review the Diagnosis, Management and Prevention of Medication-related Osteonecrosis of the Jaw. Articles will include: Osteoporosis and bone modulation therapies: indications and outcomes; Antiresorptive therapies for the treatment of malignant osteolytic bone disease; Clinical presentation and staging of antiresorptive agent-induced osteonecrosis of the jaw; Epidemiology and risk factors of antiresorptive agent-induced osteonecrosis of the jaw; Basic science research of antiresorptive agent-induced osteonecrosis of the jaw: an update; Pathophysiology of antiresorptive agent-induced osteonecrosis of the jaw: what we know and what we don’t know; The genetics of osteonecrosis of the jaw; Preventive strategies for patients at risk of antiresorptive agent-induced osteonecrosis of the jaw; Non-operative and operative therapies for treatment of antiresorptive agent-induced osteonecrosis of the jaw; The role of anti-angiogenic therapy in the development of osteonecrosis of the jaw; Antiresorptive therapies: what they are and how do they work, and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Management of MedicationrelatedOsteonecrosis of the Jaw | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | v | ||
| Preface\r | v | ||
| Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw\r | v | ||
| Pathophysiology of Osteonecrosis of the Jaws\r | v | ||
| Medication-Related Osteonecrosis of the Jaw: Basic and Translational Science Updates\r | v | ||
| The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors\r | v | ||
| Management of Medication-Related Osteonecrosis of the Jaw\r | vi | ||
| Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw\r | vi | ||
| Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw\r | vi | ||
| The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw\r | vi | ||
| Antiresorptive Therapies for Osteoporosis\r | vii | ||
| Antiresorptive Therapies for the Treatment of Malignant Osteolytic Bone Disease\r | vii | ||
| Indications and Outcomes of Osteoporosis and Bone Modulation Therapies\r | vii | ||
| ORAL AND MAXILLOFACIAL SURGERY\rCLINICS OF NORTH AMERICA\r | viii | ||
| FORTHCOMING ISSUES | viii | ||
| February 2016 | viii | ||
| May 2016 | viii | ||
| August 2016 | viii | ||
| RECENT ISSUES | viii | ||
| August 2015 | viii | ||
| May 2015 | viii | ||
| February 2015 | viii | ||
| Preface | ix | ||
| Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw | 479 | ||
| Key points | 479 | ||
| INTRODUCTION | 479 | ||
| NOMENCLATURE AND DIAGNOSTIC CRITERIA | 479 | ||
| CLINICAL PRESENTATION | 480 | ||
| IMAGING | 481 | ||
| HISTOPATHOLOGY | 482 | ||
| CLINICAL STAGING | 483 | ||
| SUMMARY | 486 | ||
| REFERENCES | 486 | ||
| Pathophysiology of Osteonecrosis of the Jaws | 489 | ||
| Key points | 489 | ||
| INTRODUCTION | 489 | ||
| PROPOSED HYPOTHESES OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW PATHOPHYSIOLOGY | 490 | ||
| Hypothesis 1: Bone-Remodeling Inhibition | 490 | ||
| Hypothesis 2: Inflammation and Infection | 491 | ||
| Hypothesis 3: Angiogenesis Inhibition | 491 | ||
| Hypothesis 4: Soft Tissue Toxicity | 492 | ||
| Hypothesis 5: Innate or Acquired Immunity Dysfunction | 492 | ||
| SUMMARY | 492 | ||
| REFERENCES | 493 | ||
| Medication-Related Osteonecrosis of the Jaw | 497 | ||
| Key points | 497 | ||
| INTRODUCTION | 497 | ||
| MEDICATION-RELATED OSTEONECROSIS OF THE JAW AT THE CELL LEVEL—BISPHOSPHONATE ACTION ON CELLS AND TISSUE ACCUMULATION | 498 | ||
| ANIMAL MODELS OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW: THE TOOLBOX IS FULL AND READY TO BE PUT TO WORK | 500 | ||
| Rodent Models | 502 | ||
| Large Animal Models | 504 | ||
| WHERE DO WE GO FROM HERE? | 505 | ||
| REFERENCES | 506 | ||
| The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors | 509 | ||
| Key points | 509 | ||
| INTRODUCTION | 509 | ||
| Challenges of Estimating the Frequency of Uncommon Diseases | 510 | ||
| SUMMARY OF FINDINGS | 510 | ||
| RISK FACTORS FOR MEDICATION-RELATED OSTEONECROSIS OF THE JAWS | 510 | ||
| Medication-related Risk Factors | 510 | ||
| Are antiresorptive or antiangiogenic agents risk factors for osteonecrosis of the jaw? | 510 | ||
| Risk for medication-related osteonecrosis of the jaws among patients with cancer | 510 | ||
| Risk for medication-related osteonecrosis of the jaws among patients treated for osteoporosis | 512 | ||
| Local Factors | 513 | ||
| Operative treatment | 513 | ||
| Anatomic factors | 513 | ||
| Concomitant oral disease | 514 | ||
| Demographic and Systemic Factors and Other Medication Factors | 514 | ||
| Genetic Factors | 514 | ||
| SUMMARY | 514 | ||
| REFERENCES | 514 | ||
| Management of Medication-Related Osteonecrosis of the Jaw | 517 | ||
| Key points | 517 | ||
| INTRODUCTION | 517 | ||
| MEDICAL MANAGEMENT | 518 | ||
| Antimicrobials | 518 | ||
| Topical antimicrobials | 518 | ||
| Oral antimicrobials | 518 | ||
| Intravenous antimicrobials | 518 | ||
| Other Medications | 518 | ||
| Pentoxifylline and vitamin E | 518 | ||
| Teriparatide | 519 | ||
| Hyperbaric Oxygen Therapy | 519 | ||
| SURGICAL MANAGEMENT | 520 | ||
| Mandibular Resection | 523 | ||
| Maxilla Resection | 523 | ||
| SUMMARY | 523 | ||
| REFERENCES | 523 | ||
| Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw | 527 | ||
| Key points | 527 | ||
| INTRODUCTION | 527 | ||
| PATIENTS AT RISK | 529 | ||
| Medication Related to Osteonecrosis of the Jaw | 529 | ||
| Bisphosphonates | 529 | ||
| Receptor activator of nuclear factor kappa-B ligand inhibitor | 529 | ||
| Angiogenesis inhibitors | 529 | ||
| PREVENTIVE STRATEGIES BEFORE COMMENCEMENT OF ANTIRESORPTIVES | 529 | ||
| Dental Screening | 529 | ||
| PREVENTIVE STRATEGIES AFTER COMMENCEMENT OF ANTIRESORPTIVES | 531 | ||
| Dentoalveolar Surgery | 531 | ||
| New Risk-reducing Strategies at Time of Extraction | 531 | ||
| Implants | 532 | ||
| Endodontics | 533 | ||
| Periodontics | 533 | ||
| Drug Holiday | 533 | ||
| SUMMARY | 534 | ||
| REFERENCES | 534 | ||
| Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw | 537 | ||
| Key points | 537 | ||
| INTRODUCTION | 537 | ||
| PHARMACOGENETICS AND ADVERSE DRUG REACTIONS | 538 | ||
| GENOME-WIDE ASSOCIATION STUDIES ON OSTEONECROSIS OF THE JAW | 538 | ||
| CANDIDATE GENE STUDIES ON OSTEONECROSIS OF THE JAW | 539 | ||
| Replication Candidate Gene Studies | 539 | ||
| Discovery Candidate Gene Studies | 542 | ||
| SUMMARY | 544 | ||
| REFERENCES | 544 | ||
| The Role of Antiangiogenic Therapy in the Development of Osteonecrosis of the Jaw | 547 | ||
| Key points | 547 | ||
| INTRODUCTION | 547 | ||
| MEDICATION-RELATED OSTEONECROSIS OF THE JAWS IN PATIENTS RECEIVING THE VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR BEVACIZ ... | 548 | ||
| MEDICATION-RELATED OSTEONECROSIS OF THE JAWS IN PATIENTS RECEIVING TYROSINE KINASE INHIBITORS, WITH AND WITHOUT ANTIRESORPT ... | 550 | ||
| MEDICATION-RELATED OSTEONECROSIS OF THE JAWS IN PATIENTS RECEIVING MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS WITH OR WITHOUT ... | 551 | ||
| MEDICATION-RELATED OSTEONECROSIS OF THE JAWS AND IMMUNOMODULATORY AGENTS WITH AN ANTIANGIOGENIC PROFILE | 552 | ||
| SUMMARY | 552 | ||
| REFERENCES | 552 | ||
| Antiresorptive Therapies for Osteoporosis | 555 | ||
| Key points | 555 | ||
| REFERENCES | 559 | ||
| Antiresorptive Therapies for the Treatment of Malignant Osteolytic Bone Disease | 561 | ||
| Key points | 561 | ||
| INTRODUCTION | 561 | ||
| PAMIDRONATE | 562 | ||
| ZOLEDRONIC ACID (ZOLEDRONATE) | 563 | ||
| DENOSUMAB | 564 | ||
| SUMMARY | 565 | ||
| REFERENCES | 565 | ||
| Indications and Outcomes of Osteoporosis and Bone Modulation Therapies | 567 | ||
| Key points | 567 | ||
| REFERENCES | 571 | ||
| Index | 573 |